SM5-1, a promising immunotherapy for Hepatocellular Carcinoma (HCC)
SM5-1, a promising immunotherapy for Hepatocellular Carcinoma (HCC)
|
Hepatocellular carcinoma (HCC), a type of liver cancer, has become one of the leading causes of cancer-related deaths, especially in Asia. Despite traditional treatments such as surgery, chemotherapy, and radiation, in recent years, tumor-targeted therapy and immunotherapy have been widely studied and considered as new and promising treatments for HCC. SM5-1 is a monoclonal antibody that can inhibit tumor cell growth and induce apoptosis. SM5-1 binds specifically to P230, a membrane protein overexpressed in several types of cancer including HCC, melanoma and breast cancer, therefore chosen as a candidate target for diagnosis and treatment. In a research published in Biomaterials, scientists developed SM5-1 conjugated gold nanoparticles (Au-SM5-1 NPs) that further enhance the immunotherapy for HCC. Au NPs help extending the retention time of SM5-1 in tumor and inhibiting the rate of cancer cell proliferation. In addition, down regulation of DUOX2 and NOX1 upon Au-SM5-1 NPs binding affects expression level of oxidase and interferes the dynamic balance of reactive oxygen species enzyme system, finally resulting in apoptosis. P21, a negative regulatory factor of cell cycle, is also up-regulated by Au-SM5-1 NPs which leads to cell cycle arrest at G1/S or G2/M phase. Finally, because of the longer retention time in tumor, accumulated Au-SM5-1 NPs subsequently inhibits angiogenesis which often cause uncontrollable tumor growth and metastasis. Studies of antibody conjugated nanoparticle provide a new approach for target therapy of different kinds of cancer. arigo is proud to provide high quality antibodies for the study of cancer and tumor metastasis. |
||
|
|
||
|
|
||
|
|
||
 |
 |
|
|
|
||
|
Tumor Metastasis Marker |
||
 |
 |
|
|
|
||
|
Apoptosis Marker ARG20041 Active PARP antibody |
||
|
ARG54155 Active Caspase 9 antibody |
||
|
|
||
